Please Remove Adblock
Adverts are the main source of Revenue for DoveMed. Please remove adblock to help us create the best medical content found on the Internet.

Molecular Testing for Dedifferentiated Liposarcoma

Last updated March 7, 2017

Molecular Testing for Dedifferentiated Liposarcoma is a genetic test that is helpful in aiding a diagnosis of dedifferentiated liposarcoma. The lab test results may also be subsequently useful in taking appropriate treatment decisions.

What are other Names for this Test? (Equivalent Terms)

  • Gene Mutation Analysis for Dedifferentiated Liposarcoma
  • Test for Molecular Diagnosis of Dedifferentiated Liposarcoma

What is Molecular Testing for Dedifferentiated Liposarcoma? (Background Information)

  • Molecular Testing for Dedifferentiated Liposarcoma is a genetic test that is helpful in aiding a diagnosis of dedifferentiated liposarcoma. The lab test results may also be subsequently useful in taking appropriate treatment decisions
  • Dedifferentiated liposarcomas are slow-growing, malignant, soft tissue tumors. These tumors are typically present in the retroperitoneum (abdominal cavity) followed by the limbs
  • A liposarcoma is a rare and malignant tumor of the fat cells. They are generally asymptomatic and can occur anywhere in the body. A dedifferentiated liposarcoma is a type of liposarcoma

The cause of dedifferentiated liposarcoma is due to genetic mutations. Currently, studies indicate defects in the following genes:

  • Amplification in MDM2 gene
  • Some tumors may have amplification in MDM2 gene with/without amplification in CDK4 gene
  • Anomalies in the following genes may be noted: HMGA2, YEATS4, CPM, FRS2JUN, ASK1 and MAP3K7IP2
  • Additionally, genetic alterations, such as supernumerary ring or giant rod marker chromosome, that may be associated with amplification in 12q14-15 with/without additional amplification as 1p32, 6q23 and 6q25 sequences, may be noted

The above genetic abnormalities can be detected using molecular studies, which may play a significant role in identifying the tumor type, and in some cases, helping the healthcare provider take appropriate treatment decisions.

The molecular testing, in general, can be performed using a variety of methods. Some of these methods include:

  • In situ hybridization technique, such as fluorescence in situ hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Next-generation sequencing (NGS)
  • Polymerase chain reaction (PCR)
  • Comparative genomic hybridization (CGH)
  • Karyotyping including spectral karyotyping
  • mRNA analysis
  • Tissue microarrays (TMAs)
  • Southern blot test
  • Northern blot test
  • Western blot test
  • Eastern blot test

The methodology used for dedifferentiated liposarcoma may vary from one laboratory to another. 

Note: Molecular testing has limitations due to the molecular method and genetic mutational abnormalities being tested. This can affect the results on a case-by-case basis. Consultation with your healthcare provider will help in determining the right test and right molecular method, based on individual circumstances.

What are the Clinical Indications for performing the Molecular Testing for Dedifferentiated Liposarcoma Test?

Molecular Testing for Dedifferentiated Liposarcoma is undertaken in the following situations: 

  • To assist (and in some cases, confirm) the initial diagnosis of dedifferentiated liposarcoma
  • To distinguish other tumors/conditions that have similar histological features, when examined by a pathologist under the microscope
  • To help in determining treatment options
  • To confirm recurrence of the tumor: Tumor recurrence can either be at the original tumor site, or at a distant location (away from the initial site)

How is the Specimen Collected for Molecular Testing for Dedifferentiated Liposarcoma?

Following is the specimen collection process for Molecular Testing for Dedifferentiated Liposarcoma:

The specimen sample requirements may vary from lab to lab. Hence, it is important to contact the testing lab for exact specimen requirements, before initiating the testing process.

  • Sample required:
    • Fresh tumor tissue during biopsy
    • Formalin-fixed paraffin-embedded solid tumor tissue (FFPE tumor tissue), often referred to as paraffin block of the tumor
    • Unstained tissue slides
  • Process of obtaining the sample: As outlined by the laboratory testing facility
  • Preparation required: As outlined by the laboratory testing facility


  • Depending on the location of testing, it may take up to 2 weeks’ turnaround time, to obtain the test results
  • Occasionally, additional samples may be required to either repeat the test or to perform follow-up testing
  • Many hospitals preserve the paraffin blocks for at least 7 years. In general, older paraffin blocks (over 5 years) may affect the detection of specific mutations, due to degradation of the tumor specimen over time

Cost of Molecular Testing for Dedifferentiated Liposarcoma:

  • The cost of the test procedure depends on a variety of factors, such as the type of your health insurance, annual deductibles, co-pay requirements, out-of-network and in-network of your healthcare providers and healthcare facilities
  • In many cases, an estimate may be provided before the test is conducted. The final amount may depend upon the findings during the test procedure and post-operative care that is necessary (if any)

What is the Significance of the Molecular Testing for Dedifferentiated Liposarcoma Result?

The significance of Molecular Testing for Dedifferentiated Liposarcoma is explained:

  • Presence of a positive test result helps aid, and in some cases, confirm the diagnosis of dedifferentiated liposarcoma
  • The result can help exclude other tumors with similar histological features
  • It can help determine the prognosis of the patient
  • In some cases, the test results may help in taking treatment decisions

The laboratory test results are NOT to be interpreted as results of a "stand-alone" test. The test results have to be interpreted after correlating with suitable clinical findings and additional supplemental tests/information. Your healthcare providers will explain the meaning of your tests results, based on the overall clinical scenario.

Additional and Relevant Useful Information:

  • Many laboratories may not have the capability to perform this test. Only highly-specialized labs with advanced facilities and testing procedures may perform this test
  • Additional mutations are still being discovered in many of these tumors. This may further contribute towards tumor diagnosis and treatment. Please consult with your healthcare provider for any information updates

Certain medications that you may be currently taking may influence the outcome of the test. Hence, it is important to inform your healthcare provider of the complete list of medications (including any herbal supplements) you are currently taking. This will help the healthcare provider interpret your test results more accurately and avoid unnecessary chances of a misdiagnosis.

What are some Useful Resources for Additional Information?

The following DoveMed website link is a useful resource for additional information:


Please visit our Laboratory Procedures Center for more physician-approved health information:


References and Information Sources used for the Article:

https://ghr.nlm.nih.gov/primer/testing/genetictesting (accessed on 02/17/2017)

https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5806a1.htm (accessed on 02/17/2017)

http://www.nature.com/gim/journal/v10/n5/full/gim200852a.html (accessed on 02/17/2017)

http://pediatrics.aappublications.org/content/106/6/1494 (accessed on 02/17/2017)

https://www.hindawi.com/journals/sarcoma/2011/483154/ (accessed on 02/17/2017)

http://bmcclinpathol.biomedcentral.com/articles/10.1186/1472-6890-14-36 (accessed on 02/17/2017)

http://cancerres.aacrjournals.org/content/67/14/6626 (accessed on 02/17/2017)

Helpful Peer-Reviewed Medical Articles:

Carrano, A. V., et al. Measurement and purification of human chromosomes by flow cytometry and sorting. Proceedings of the National Academy of Sciences 76, 1382–1384 (1979)

Drets, M. E., & Shaw, M. W. Specific banding patterns of human chromosomes. Proceedings of the National Academy of Sciences 68, 2073–2077 (1971)

Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002)

Parra, I., & Windle, B. High resolution visual mapping of stretched DNA by fluorescent hybridization. Nature Genetics 5, 17–21 (1993) doi:10.1038/ng0993-17

Pinkel, D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics 20, 207–211 (1998) doi:10.1038/2524

Speicher, M. R., et al. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genetics 12, 368–375 (1996) doi:10.1038/ng0496-368

Ray-Coquard, I., Blay, J. Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., ... & Geho, D. (2012). Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. The lancet oncology, 13(11), 1133-1140.

Coindre, J. M., Pédeutour, F., & Aurias, A. (2010). Well-differentiated and dedifferentiated liposarcomas. Virchows Archiv, 456(2), 167-179.

Crago, A. M., & Singer, S. (2011). Clinical and molecular approaches to well-differentiated and dedifferentiated liposarcoma. Current opinion in oncology, 23(4), 373.

Mariño-Enríquez, A., Fletcher, C. D., Dal Cin, P., & Hornick, J. L. (2010). Dedifferentiated liposarcoma with “homologous” lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. The American journal of surgical pathology, 34(8), 1122-1131.

Peng, T., Zhang, P., Liu, J., Nguyen, T., Bolshakov, S., Belousov, R., ... & Oliveira, A. M. (2011). An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Laboratory investigation, 91(3), 392-403.

Ghadimi, M. P., Al-Zaid, T., Madewell, J., Peng, T., Colombo, C., Hoffman, A., ... & Pollock, R. E. (2011). Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Annals of surgical oncology, 18(13), 3762-3770.

Sioletic, S., Dal Cin, P., Fletcher, C. D., & Hornick, J. L. (2013). Well‐differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases. Histopathology, 62(2), 287-293.

Keung, E. Z., Hornick, J. L., Bertagnolli, M. M., Baldini, E. H., & Raut, C. P. (2014). Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. Journal of the American College of Surgeons, 218(2), 206-217.

Rieker, R. J., Weitz, J., Lehner, B., Egerer, G., Mueller, A., Kasper, B., ... & Mechtersheimer, G. (2010). Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Archiv, 456(3), 277-285.

Crago, A. M., Socci, N. D., DeCarolis, P., O'Connor, R., Taylor, B. S., Qin, L. X., ... & Singer, S. (2012). Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clinical Cancer Research, 18(5), 1334-1340.

Reviewed and Approved by a member of the DoveMed Editorial Board
First uploaded: March 7, 2017
Last updated: March 7, 2017